文献速递细菌感染、耐药与抗菌药物

口服β-内酰胺类抗生素联用丙磺舒:系统综述与荟萃分析

Addition of probenecid to oral β-lactam antibiotics: a systematic review and meta-analysis.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

该系统综述与荟萃分析检索Medline和EMBASE至2021年12月,纳入18项比较口服β-内酰胺类单用与联用丙磺舒的研究,发现丙磺舒可提高β-内酰胺类总AUC、Cmax和血清半衰期;对3105例淋球菌病患者荟萃分析显示,丙磺舒组治疗失败风险低于对照组(RR 0.33,95%CI 0.20-0.55;I²=7%)。

要点

  • 丙磺舒联用口服β-内酰胺类可提高总AUC(7/7研究)、Cmax(5/8)和血清半衰期(6/8)。
  • 淋球菌病患者荟萃分析显示,丙磺舒组治疗失败风险低于对照组(RR 0.33,95%CI 0.20-0.55;I²=7%)。
  • 药代动力学数据提示丙磺舒增效口服β-内酰胺类可能有更广泛应用,但需设计良好的机制和疗效研究。

核心结论

  • 丙磺舒增效的β-内酰胺类治疗与淋球菌病转归改善相关。
  • 药代动力学数据提示丙磺舒增效口服β-内酰胺类治疗可能有更广泛应用,但需设计良好的机制和疗效研究。

研究设计与样本

  • 系统综述与荟萃分析,检索Medline和EMBASE自建库至2021年12月的英文研究。
  • 纳入18/295(6%)篇筛选摘要,比较口服β-内酰胺类联用丙磺舒(干预)与单用口服β-内酰胺类(对照)。
  • 对照药物包括氟氯西林、青霉素V、阿莫西林(±克拉维酸)、头孢氨苄、头孢呋辛酯。
  • 使用ROBINS-I和ROB-2工具评估偏倚风险。
  • 常见人群为健康志愿者(9/18;50%)和淋球菌感染者(6/18;33%)。

主要发现

  • 丙磺舒联用口服β-内酰胺类提高总AUC(7/7;100%)、Cmax(5/8;63%)和血清t½(6/8;75%)。
  • 丙磺舒改善PTA(2/2;100%)。
  • 对3105例(干预2258例,对照847例)淋球菌病患者荟萃分析,随机效应模型治疗失败RR为0.33(95%CI 0.20-0.55;I²=7%),有利于丙磺舒组。
  • 研究间人群、方法和结局数据存在异质性。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 研究间人群、方法和结局数据存在异质性。
  • 需设计良好的机制和疗效研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To explore the literature comparing the pharmacokinetic and clinical outcomes from adding probenecid to oral β-lactams. METHODS: Medline and EMBASE were searched from inception to December 2021 for all English language studies comparing the addition of probenecid (intervention) with an oral β-lactam [flucloxacillin, penicillin V, amoxicillin (± clavulanate), cefalexin, cefuroxime axetil] alone (comparator). ROBINS-I and ROB-2 tools were used. Data on antibiotic therapy, infection diagnosis, primary and secondary outcomes relating to pharmacokinetics and clinical outcomes, plus adverse events were extracted and reported descriptively. For a subset of studies comparing treatment failure between probenecid and control groups, meta-analysis was performed. RESULTS: Overall, 18/295 (6%) screened abstracts were included. Populations, methodology and outcome data were heterogeneous. Common populations included healthy volunteers (9/18; 50%) and those with gonococcal infection (6/18; 33%). Most studies were crossover trials (11/18; 61%) or parallel-arm randomized trials (4/18; 22%). Where pharmacokinetic analyses were performed, addition of probenecid to oral β-lactams increased total AUC (7/7; 100%), Cmax (5/8; 63%) and serum t½ (6/8; 75%). Probenecid improved PTA (2/2; 100%). Meta-analysis of 3105 (2258 intervention, 847 control) patients treated for gonococcal disease demonstrated a relative risk of treatment failure in the random-effects model of 0.33 (95% CI 0.20-0.55; I2 = 7%), favouring probenecid. CONCLUSIONS: Probenecid-boosted β-lactam therapy is associated with improved outcomes in gonococcal disease. Pharmacokinetic data suggest that probenecid-boosted oral β-lactam therapy may have a broader application, but appropriately powered mechanistic and efficacy studies are required.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Wilson RC, Arkell P, Riezk A, et al. Addition of probenecid to oral β-lactam antibiotics: a systematic review and meta-analysis. J Antimicrob Chemother. 2022. PMID: 35726853. doi:10.1093/jac/dkac200

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。